Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2001

View Archived Issues

Valentis highlights significant events over past year

Innogenetics updates product pipeline

FDA approves TAP's Spectracef

Devgen and Metabolex work together in the area of diabetes

U.S. Ethyol rights to be returned to MedImmune by October 1, 2001

deCODE locates genes linked to obesity and anxiety in a collaboration with Roche

ATL-193 and ATL-146e as pharmacological stress agents for myocardial perfusion imaging

Non-nucleoside-containing tricyclic platelet P2Y12 receptor antagonist characterized

Thirty-six-week follow-up data show maintenance of weight loss after treatment with Axokine

Potential new drug for removing cholesterol licensed to Samaritan

AERx iDMS showcased at EASD meeting

Men with diabetes-related ED respond well to on-demand treatment with IC-351

Oncolytics Biotech continues to make progress with reovirus as cancer therapy

Ferrochloroquine: high antimalarial activity coupled with lack of significant crossresistance

Procyon highlights Q2 developments

Fourth human beta-defensin peptide identified and characterized

Norwegian collaboration focuses on human antibodies for infectious diseases

PhotoCure prepares for Metvix launch; Hexvix development progressing as planned

Enrollment completed in pivotal Alzheimer's disease trial of Neotrofin

Myriad Genetics highlights development progress

Adapalene and pharmaceutical compositions thereof for use in cancer therapy

New ribozyme modulates CHK1 gene expression

Spiro protein farnesyltransferase inhibitors designed by Merck scientists

Novel PDE4 and TNF-alpha inhibitors in the Pfizer pipeline

Recent patent covers hydroxamic acid-based inhibitors of sCD23

Merck Frosst/AxyS collaboration identifies new cathepsin inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...